Deciphera Pharmaceuticals, LLC
Records under this name other than the patents Deciphera Pharmaceuticals, LLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 77 patents it holds.
Back to Deciphera Pharmaceuticals, LLC
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,850,240 | Compositions of 1-(4-Bromo-5-(1-Ethyl-7-(METHYLAMINO)-2-OXO-1,2-Dihydro-1,6-Naphthyridin-3-YL)-2-Fluoropheyl)-3-Phenylurea Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 12,509,456 | Solid State Forms of Ripretinib Formerly held In force · High confidence | In force | High confidence | |
| US 9,187,474 | Raf Inhibitor Compounds Lapsed on the fee record Ended Nov 17, 2023 · High confidence | Lapsed on the fee record | Ended Nov 17, 2023 | High confidence |
| US 8,921,565 | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities Lapsed on the fee record Ended Dec 30, 2022 · From the USPTO record | Lapsed on the fee record | Ended Dec 30, 2022 | From the USPTO record |
| US 8,637,672 | Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activities Lapsed on the fee record Ended Jan 28, 2022 · From the USPTO record | Lapsed on the fee record | Ended Jan 28, 2022 | From the USPTO record |
| US 8,569,319 | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities Lapsed on the fee record Ended Oct 29, 2021 · From the USPTO record | Lapsed on the fee record | Ended Oct 29, 2021 | From the USPTO record |
| US 8,940,756 | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases Surrendered on reissue Surrendered on reissue Sep 14, 2021 · From the USPTO record | Surrendered on reissue | Surrendered on reissue Sep 14, 2021 | From the USPTO record |
| US 8,278,331 | N-acyl ureas exhibiting anti-cancer and anti-proliferative activities Lapsed on the fee record Ended Oct 2, 2020 · From the USPTO record | Lapsed on the fee record | Ended Oct 2, 2020 | From the USPTO record |
| US 9,387,202 | Pyridone Amides and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities Lapsed on the fee record Ended Jul 12, 2020 · Medium confidence | Lapsed on the fee record | Ended Jul 12, 2020 | Medium confidence |
| US 9,334,267 | Raf Inhibitor Compounds Lapsed on the fee record Ended May 10, 2020 · High confidence | Lapsed on the fee record | Ended May 10, 2020 | High confidence |